Is there a generic version of Zenocutuzumab available?

As of now, there is no generic version of Zenocutuzumab (Zenocutuzumab) on the market. The drug was developed by the Dutch biopharmaceutical company Merus under the trade name Bizengri and will be released in 2024 year12obtained accelerated approval from the U.S.FDA in September for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and pancreatic cancer carrying NRG1 gene fusions . Currently, the drug only exists in the form of the original drug on the U.S. market, and no generic version has yet appeared.

Zetolizumab is a bispecific antibody that targets HER2 and HER3 receptors. It is mainly used to treat tumors carrying NRG1 gene fusion. Due to the specificity of its mechanism of action and precise therapeutic targeting of specific gene mutations, zetolizumab has shown significant efficacy in the treatment of the above types of cancers. However, the specificity of this targeted therapy also means that its market demand is relatively limited, which may affect the development momentum of generic drugs.

At present, zetolizumab has not yet received marketing approval in China. If domestic patients need to use the drug, they may need to obtain it through overseas drug purchase channels. However, since there is no generic version of the drug, patients can only choose the original drug, which may result in higher treatment costs. In addition, there are certain risks involved in purchasing drugs overseas, including issues such as drug authenticity and quality assurance during transportation. Patients should be cautious when choosing.

Overall, zetolizumab, as an innovative targeted therapy, has potential advantages in the treatment of cancers driven by specific genetic mutations. However, there is currently no generic version on the market and it has not yet been approved in the Chinese market. Patients must face higher costs and certain risks when using it. In the future, with the accumulation of more clinical data and policy promotion, zetolizumab may gradually enter the Chinese market, and a generic version is expected to appear, thereby reducing the economic burden on patients.

Reference materials:https://www.drugs.com/